These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 27486808)

  • 21. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.
    Proto C; Imbimbo M; Gallucci R; Brissa A; Signorelli D; Vitali M; Macerelli M; Corrao G; Ganzinelli M; Greco FG; Garassino MC; Lo Russo G
    Transl Lung Cancer Res; 2016 Dec; 5(6):563-578. PubMed ID: 28149752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study.
    Ekman S; Cselényi Z; Varrone A; Jucaite A; Martin H; Schou M; Johnström P; Laus G; Lewensohn R; Brown AP; van der Aart J; Vishwanathan K; Farde L
    Clin Transl Sci; 2023 Jun; 16(6):955-965. PubMed ID: 36808835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of osimertinib against EGFRvIII+ glioblastoma.
    Chagoya G; Kwatra SG; Nanni CW; Roberts CM; Phillips SM; Nullmeyergh S; Gilmore SP; Spasojevic I; Corcoran DL; Young CC; Ballman KV; Ramakrishna R; Cross DA; Markert JM; Lim M; Gilbert MR; Lesser GJ; Kwatra MM
    Oncotarget; 2020 Jun; 11(22):2074-2082. PubMed ID: 32547705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A PET study in healthy subjects of brain exposure of
    Varrone A; Varnäs K; Jucaite A; Cselényi Z; Johnström P; Schou M; Vazquez-Romero A; Moein MM; Halldin C; Brown AP; Vishwanathan K; Farde L
    J Cereb Blood Flow Metab; 2020 Apr; 40(4):799-807. PubMed ID: 31006308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice.
    Higuchi T; Oshiro H; Zhang Z; Miyake K; Sugisawa N; Katsuya Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Zhao M; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Transl Oncol; 2019 Apr; 12(4):640-645. PubMed ID: 30807997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osimertinib for
    Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
    Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases.
    Kong LL; Wang LL; Xing LG; Yu JM
    Chronic Dis Transl Med; 2017 Dec; 3(4):221-229. PubMed ID: 29354805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.
    McGranahan T; Nagpal S
    Curr Treat Options Oncol; 2017 Apr; 18(4):22. PubMed ID: 28391420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
    Saad N; Poudel A; Basnet A; Gajra A
    Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung.
    Reichegger H; Jochum W; Förbs D; Hader C; Früh M
    Oncol Res Treat; 2016; 39(7-8):461-3. PubMed ID: 27486808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
    Joo JW; Hong MH; Shim HS
    Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
    Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
    Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.
    Koba T; Kijima T; Takimoto T; Hirata H; Naito Y; Hamaguchi M; Otsuka T; Kuroyama M; Nagatomo I; Takeda Y; Kida H; Kumanogoh A
    Medicine (Baltimore); 2017 Feb; 96(6):e6087. PubMed ID: 28178168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of osimertinib in EGFR-mutated non-small cell lung cancer.
    Mezquita L; Varga A; Planchard D
    Expert Opin Drug Saf; 2018 Dec; 17(12):1239-1248. PubMed ID: 30457891
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.